Celgene has agreed to pay Epizyme US$90 M upfront, including an equity investment, as part of a deal to discover, develop and commercialise histone methyltransferase (HMT) inhibitors for patients with genetically defined cancers. Celgene will gain ex-US rights to Epizyme’s DOT1L HMT inhibitor programme as well as an exclusive option to license the company’s unpartnered HMT inhibitor programmes over a 3-year period, extendable for 1 year.